Clinic III for Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.
Sci Rep. 2021 Nov 29;11(1):23066. doi: 10.1038/s41598-021-02480-z.
The effect of respiratory infectious diseases on STEMI incidence, but also STEMI care is not well understood. The Influenza 2017/2018 epidemic and the COVID-19 pandemic were chosen as observational periods to investigate the effect of respiratory virus diseases on these outcomes in a metropolitan area with an established STEMI network. We analyzed data on incidence and care during the COVID-19 pandemic, Influenza 2017/2018 epidemic and corresponding seasonal control periods. Three comparisons were performed: (1) COVID-19 pandemic group versus pandemic control group, (2) COVID-19 pandemic group versus Influenza 2017/2018 epidemic group and (3) Influenza 2017/2018 epidemic group versus epidemic control group. We used Student's t-test, Fisher's exact test and Chi square test for statistical analysis. 1455 patients were eligible. The daily STEMI incidence was 1.49 during the COVID-19 pandemic, 1.40 for the pandemic season control period, 1.22 during the Influenza 2017/2018 epidemic and 1.28 during the epidemic season control group. Median symptom-to-contact time was 180 min during the COVID-19 pandemic. In the pandemic season control group it was 90 min (p = 0.183), and in the Influenza 2017/2018 cohort it was 90 min, too (p = 0.216). Interval in the epidemic control group was 79 min (p = 0.733). The COVID-19 group had a door-to-balloon time of 49 min, corresponding intervals were 39 min for the pandemic season group (p = 0.038), 37 min for the Influenza 2017/2018 group (p = 0.421), and 38 min for the epidemic season control group (p = 0.429). In-hospital mortality was 6.1% for the COVID-19 group, 5.9% for the Influenza 2017/2018 group (p = 1.0), 11% and 11.2% for the season control groups. The respiratory virus diseases neither resulted in an overall treatment delay, nor did they cause an increase in STEMI mortality or incidence. The registry analysis demonstrated a prolonged door-to-balloon time during the COVID-19 pandemic.
呼吸道传染病对 STEMI 发病率的影响，以及 STEMI 治疗的情况也尚未得到充分认识。选择 2017/2018 年流感流行季和 COVID-19 大流行作为观察期，旨在调查呼吸道病毒疾病对大都市地区 STEMI 网络中这些结果的影响。我们分析了 COVID-19 大流行期间、2017/2018 年流感流行季及其相应季节性对照组的数据。进行了 3 项比较：（1）COVID-19 大流行组与大流行对照组，（2）COVID-19 大流行组与 2017/2018 年流感流行组，（3）2017/2018 年流感流行组与流行季对照组。我们使用学生 t 检验、Fisher 确切检验和卡方检验进行统计学分析。符合条件的患者共 1455 例。COVID-19 大流行期间的每日 STEMI 发病率为 1.49，大流行季节对照组为 1.40，2017/2018 年流感流行季为 1.22，流行季对照组为 1.28。COVID-19 大流行期间的症状至就诊时间中位数为 180 分钟。在大流行季节对照组中为 90 分钟（p=0.183），在 2017/2018 年流感队列中也为 90 分钟（p=0.216）。在流行季对照组中为 79 分钟（p=0.733）。COVID-19 组的门球时间为 49 分钟，相应的间隔分别为大流行季节组的 39 分钟（p=0.038），2017/2018 年流感组的 37 分钟（p=0.421）和流行季对照组的 38 分钟（p=0.429）。COVID-19 组的院内死亡率为 6.1%，2017/2018 年流感组为 5.9%（p=1.0），两个流行季对照组的死亡率分别为 11%和 11.2%。呼吸道病毒疾病既没有导致整体治疗延迟，也没有导致 STEMI 死亡率或发病率增加。注册分析显示，COVID-19 大流行期间门球时间延长。
